Protalix BioTherapeutics (PLX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$29.4 million.
- Protalix BioTherapeutics' Enterprise Value fell 715.46% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 715.46%. This contributed to the annual value of -$34.8 million for FY2024, which is 2183.57% up from last year.
- Per Protalix BioTherapeutics' latest filing, its Enterprise Value stood at -$29.4 million for Q3 2025, which was down 715.46% from -$33.4 million recorded in Q2 2025.
- In the past 5 years, Protalix BioTherapeutics' Enterprise Value ranged from a high of -$20.8 million in Q3 2022 and a low of -$76.9 million during Q2 2021
- In the last 5 years, Protalix BioTherapeutics' Enterprise Value had a median value of -$34.8 million in 2024 and averaged -$40.0 million.
- In the last 5 years, Protalix BioTherapeutics' Enterprise Value plummeted by 11989.14% in 2021 and then soared by 6286.2% in 2022.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Enterprise Value stood at -$39.0 million in 2021, then soared by 43.11% to -$22.2 million in 2022, then tumbled by 100.9% to -$44.6 million in 2023, then grew by 21.84% to -$34.8 million in 2024, then increased by 15.68% to -$29.4 million in 2025.
- Its last three reported values are -$29.4 million in Q3 2025, -$33.4 million for Q2 2025, and -$34.7 million during Q1 2025.